SCHEMBL1450673

SCHEMBL1450673

CCOC(=O)/C=C1\CCOc2cc(C(F)(F)F)ccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
RECQL P46063 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 2/20 0.39
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.39
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37
GLA P06280 1/20 0.37
RAB9A P51151 1/20 0.37
TDP1 Q9NUW8 2/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
ESR2 Q92731 1/20 0.36
MAPT P10636 1/20 0.35
CNR2 P34972 1/20 0.35
OGA O60502 1/20 0.35
GAA P10253 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1861927 1.00 CYP11B1 (0.39) CYP11B1CYP11B2RECQLSMN1; SMN2NPSR1
SCHEMBL12630105 0.93 CYP11B1 (0.40) CYP11B1CYP11B2RECQLSMN1; SMN2NPSR1
SCHEMBL12630116 0.93 CYP11B1 (0.40) CYP11B1CYP11B2RECQLSMN1; SMN2NPSR1
SCHEMBL1451062 0.90 TRPV1 (0.41) KDM4ENPC1TP53GLARAB9A
SCHEMBL13538772 0.83 OGA (0.38) CYP11B1CYP11B2NPC1RAB9ATDP1
SCHEMBL24867670 0.82 ALDH1A1 (0.39) SMN1; SMN2POLBNPC1TP53GLA
SCHEMBL31021614 0.82 ALDH1A1 (0.39) SMN1; SMN2POLBNPC1TP53GLA
SCHEMBL1451522 0.82 PRMT5 (0.37) KDM4ENPC1RAB9APRMT5WDR77
SCHEMBL29633435 0.82 PRMT5 (0.37) KDM4ENPC1RAB9APRMT5WDR77
SCHEMBL1451524 0.82 PRMT5 (0.37) KDM4ENPC1RAB9APRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383839-B2 Heterocyclidene acetamide derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2013-02-26 US disclosed
US-8383839-B2 Heterocyclidene acetamide derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2013-02-26 US disclosed
US-20110112071-A1 NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2011-05-12 US disclosed
US-20110112071-A1 NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2011-05-12 US disclosed
US-20110112071-A1 NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2011-05-12 US disclosed
US-7910751-B2 Heterocyclidene acetamide derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2011-03-22 US disclosed
US-7910751-B2 Heterocyclidene acetamide derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2011-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112071-A1 NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE TRPV1, TRPV3, TRPA1 CYP11B1 2051/4885CYP11B2 2277/4885RECQL 2845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.